Drug Profile

GIGA 2339

Alternative Names: GIGA-2339

Latest Information Update: 27 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GigaGen
Class Antivirals; Immunoglobulins; Polyclonal antibodies
Mechanism of Action Hepatitis B virus replication inhibitors; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Hepatitis B

Most Recent Events

19 Nov 2024 Phase-I clinical trials in Hepatitis B (Parenteral)
01 Aug 2024 US FDA approves IND application for GIGA 2339 in Hepatitis B virus infection
31 Jul 2024 GigaGen plans a phase I trial in Hepatitis B virus infection in quarter 4 of 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com